Land: Verenigd Koninkrijk
Taal: Engels
Bron: MHRA (Medicines & Healthcare Products Regulatory Agency)
Magnesium hydroxide; Aluminium hydroxide gel dried
Rosemont Pharmaceuticals Ltd
A02AD01
Magnesium hydroxide; Aluminium hydroxide gel dried
39mg/1ml ; 44mg/1ml
Oral suspension
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 01010100; GTIN: 5050204100667
OBJECT 1 MUCOGEL SUSPENSION Summary of Product Characteristics Updated 30-Jun-2017 | Chemidex Pharma Ltd 1. Name of the medicinal product MUCOGEL SUSPENSION 2. Qualitative and quantitative composition Each 5ml dose contains: Aluminium Hydroxide Gel BP Magnesium Hydroxide BP 220mg 195mg 3. Pharmaceutical form Antacid suspension for oral administration. 4. Clinical particulars 4.1 Therapeutic indications Antacid therapy in gastric and duodenal ulcer, gastritis, heartburn, gastric hyperacidity. Treatment of indigestion. Relief of symptoms of heartburn and dyspepsia associated with gastric reflux in hiatus hernia, reflux oesophagitis and similar conditions. 4.2 Posology and method of administration Adults, elderly and children over 12 years of age: 10-20ml three times daily 20 minutes to one hour after meals, and at bedtime, or as required. Children under 12 years of age: Not recommended. 4.3 Contraindications Should not be used in patients who are severely debilitated or suffering from kidney failure. 4.4 Special warnings and precautions for use None stated. 4.5 Interaction with other medicinal products and other forms of interaction Antacids inhibit the absorption of tetracyclines and vitamins and should not be taken concomitantly. 4.6 Pregnancy and lactation For Mucogel Suspension no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women. 4.7 Effects on ability to drive and use machines None stated. 4.8 Undesirable effects Gastrointestinal side-effects are uncommon. This formulation minimises the problems of diarrhoea and constipation. REPORTING OF SUSPECTED ADVERSE REACTIONS Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to repor Lees het volledige document